2020 ACCP Virtual Journal Club May | Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds - On Demand
Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds- On Demand
ACCP Virtual Journal Club Webinars
Live Session: Wednesday, May 20, 2020 from 2:00-3:00 PM ET
On Demand: May 20, 2020 to May 20, 2023
See Handouts tab for Continuing Education information on IPCE credits.
Why is this webinar important to you?
Target-mediated drug disposition (TMDD) is a term to describe a nonlinear pharmacokinetics (PK) phenomenon that is caused by high-affinity binding of a compound to its pharmacologic targets. As the interaction between drug and its pharmacologic target belongs to the process of pharmacodynamics (PD), TMDD can be viewed as a consequence of “PD affecting PK”. Both large-molecule and small-molecule compounds can undergo TMDD. Learners that complete this course will explain how TMDD happens; why large-molecule and small-molecule compounds exhibiting TMDD demonstrate substantially different nonlinear PK behaviors; what nonlinear PK profiles look like in large-molecule and small-molecule compounds exhibiting TMDD; and how to identify whether the nonlinear PK of a compound is because of TMDD.
Guohua An, MD, PhD
Dr. An joined Ruijin Hospital for 2 years as a clinical pharmacist and research scientist after receiving her MD from Taishan Medical College and MS in Clinical Pharmacology from Fudan Univ. Then she pursued a further study and got her PhD degree in Pharmaceutical Sciences from SUNY at Buffalo. Her graduate research focused on the role of transporter on the pharmacokinetics (PK) and pharmacodynamics (PD) of anticancer agents. Her research was further expanded after she joined the R&D group of Abbott, where she gained extensive hands on experience in clinical drug development, PK/PD modeling and simulation. Prior to joining Univ of Iowa, Dr. An worked at Univ of Florida as an Assistant Professor for one and half years. Her research interests include mechanism-based PK/PD modeling, model-informed drug development, pediatric clinical pharmacology, quantitative systems pharmacology, as well as applying proteomics in allometric scaling and IVIVE. Dr. An has been in the PK/PD field for 15 years and has published 66 peer-reviewed articles. Dr. An serves as an editorial board member for The Journal of Clinical Pharmacology (since 2014), Journal of Pharmaceutical Sciences (since 2016), and The AAPS Journal (since 2020).
Alexander J. Prokopienko, PharmD, PhD (Moderator)
Dr. Prokopienko graduated from Albany Coll of Pharmacy with his PharmD and subsequently from the Univ of Pittsburgh with his PhD in Clinical Pharmaceutical Sciences. During his PhD, Alex was selected as a recipient of the AFPE Pre-Doctoral fellowship, NIH TL1 Post-Doctoral fellowship and NIH Clinical Research Loan Repayment Program. After completing his PhD, he joined Vertex Pharmaceuticals as a Clinical Pharmacologist.